Simeconazole is a demethylation inhibitor-class fungicide. Simeconazole prevents the infection of barley leaves by Blumeria graminis f sp hordei, inhibits the development of powdery mildew on barley and cucumber leaves, and exhibits cuticular membrane permeability in tomato fruits. Simeconazole can be used in research related to barley powdery mildew and cucumber powdery mildew.

Sim-9 is a covalent allosteric inhibitor of interferon regulatory factor 3 (IRF3). Sim-9 binds covalently to the Cys222 residue of IRF3, induces its conformational change, blocks its interactions with TRIF, MAVS and STING, and inhibits IRF3 homodimerization and type I interferon response. Sim-9 exhibits significant anti-inflammatory, organ-protective and survival benefits in mouse models of sepsis and acute pancreatitis. Sim-9 can be used for research related to inflammatory diseases.

SIK2/3-IN-3 (Example 15) is a potent, selective SIK2/3 inhibitor that exhibits preferential inhibitory activity against SIK2 (IC50 = 10.3 nM) and SIK3 (IC50 = 0.8 nM) over SIK1 (IC50 = 801 nM). SIK2/3-IN-3 can be used for the study of inflammatory diseases.

SIK2/3-IN-2 (compound 12, compound I-200) is a potent SIK2/3 inhibitor (SIK2 IC50 = 65 nM, SIK3 IC50 = 14 nM). SIK2/3-IN-2 is also a p21-activated protein kinase (PAK) 1 inhibitor with a Ki of 20.7 nM. SIK2/3-IN-2 can be used for hyperproliferative diseases and cancer research, such as Paclitaxel-resistant ovarian cancer.

SIAIS001 is a potent and orally active PROTAC ALK degrader with a DC50 of 3.9 nM. SIAIS001 induces G1/S phase cell cycle arrest and inhibits proliferation of SR cells (IC50 = 0.9 nM). SIAIS001 can be used for non-small cell lung cancer (NSCLC) and anaplastic large-cell lymphomas (ALCLs) research. (Pink: Anaplastic lymphoma kinase (ALK) ligand ; Blue: TNF Receptor ligand ; Black: linker).

SHP2-IN-46 is an orally active SHP2 inhibitor (IC50 = 11.76 μM). SHP2-IN-46 inhibits SHP2 enzymatic activity and mediates anti-tumor activity. SHP2-IN-46 suppresses cell proliferation in various cancer cells. SHP2-IN-46 can be used in research related to lung adenocarcinoma, pancreatic cancer and hepatoblastoma.

SHK1112218 is an orally active mitochondrial proton carrier with an EC50 of 0.48 μM. SHK1112218 restores proton transport and increases oxygen consumption rate. SHK1112218 can be used for the research of diabetes, obesity, and metabolic dysfunction-associated steatotic liver disease.

SH-273 is a dual targeting compound. SH-273 has dual function to stimulate STING function (EC50: 100 nM) and inhibits PI3Kγ (IC50: 7 nM). SH-273 can be used in the research of pancreatic cancer.

SGS-518 is a selective 5-HT6R antagonist. SGS518 can be used for the research of cognitive impairments such as amnesia, anxiety and depression, and it is effective in protecting mouse retina at high doses.

SGK1-IN-9 (Compound 1) is a SGK1 inhibitor. SGK1-IN-9 can be used in cancer research.

SGK1-IN-8 (compound 55) is a SGK1 and GSK3β inhibitor, with an IC50 of 0.11 μM against human SGK1 and an IC50 of 3.39 μM against human GSK3β. SGK1-IN-8 inhibits the catalytic activities of SGK1 and GSK3β, and reduces the phosphorylation level of TAU protein at the Ser214 site. SGK1-IN-8 is available for the research of Alzheimer's disease.

SGK1-IN-7 is a blood-brain barrier-permeable SGK1 inhibitor with an IC50 of 0.72 μM. SGK1-IN-7 reduces the phosphorylation level of TAU protein at the Ser396 and Ser214 epitopes. SGK1-IN-7 antagonizes the toxicity induced by Okadaic acid. SGK1-IN-7 can be used in the research of Alzheimer's disease.

SGI-1776-VHL-02-epimer (SGI-1776-cis-VHL-02) is an epimer control compound of with SGI-1776-VHL-02. SGI-1776-VHL-02-epimer has an inverted stereocenter in the critical hydroxyl-proline group in the VHL ligand. SGI-1776-VHL-02-epimer cannot trigger the VHL E3 ligase complex and does not degrade PIM1.

SGI-1776-VHL-02 is a stereoselective PIM PROTAC degrader. SGI-1776-VHL-02 promotes the ubiquitination and degradation of PIM1, PIM2 and PIM3. SGI-1776-VHL-02 downregulates c-myc protein levels, induces Apoptosis, and reduces the colony-forming ability of prostate cancer cells. SGI-1776-VHL-02 can be used in studies related to prostate cancer. (Pink: Pim and Autophagy and Apoptosis ligand ; Blue: Ligands for E3 Ligase and VHL ligand ; Black: linker ).

SG-210 (SPR 210) is an orally active and selective aldose reductase (AR) inhibitor. SG-210 has IC50 values of 9.5 nM and 10 nM for AR from porcine lens and human placenta, respectively. SG-210 can inhibit sorbitol accumulation and ameliorate diabetic neuropathy and retinopathy in Streptozotocin-induced diabetic rats. SG-210 can be used in the research of diseases such as diabetes-related complications.

SET7-IN-DC21 is a selective, potent SET7 inhibitor (IC50 = 15.93 μM; KD = 18.00 μM). SET7-IN-DC21 has good selectivity for several other epigenetic targets, such as SUV39H1, G9a, NSD1, DOT1L and MOF. SET7-IN-DC21 can be used for the researches of cancer, infection, inflammation, metabolic and cardiovascular disease, such as breast cancer.

Serotonin O-phosphate is a metabolite of Tryptamine.

SePP is a blood-brain barrier-permeable NMDAR antagonist and dopamine/norepinephrine reuptake inhibitor, with a Ki of 28.7 nM for rat NMDAR. SePP exerts anticonvulsant effects. SePP can be used in research related to fragile X syndrome.

Sepetaprost (ONO-9054) is a dual agonist of prostaglandin E3 receptor and prostaglandin F receptor. Sepetaprost can reduce intraocular pressure and can be used for the researches of ocular hypertension and open angle glaucoma.

Senkyunolide R is a phthalide compound that can be naturally extracted from the dried rhizomes of Ligusticum chuanxiong HORT.

Selnoflast (RO7486967) monopotassium, formerly somalix/RG6418/IZD334 monopotassium, is an orally active, potent, selective and reversible small molecule NLRP3 inflammasome inhibitor. Selnoflast monopotassium is a potent inhibitor of IL-1β release stimulated by NLRP3 activation in human Alzheimer's disease (AD) monocyte-derived macrophages. Selnoflast monopotassium is promising for research of AD and systemic inflammatory diseases, such as ulcerative colitis and chronic obstructive pulmonary disease.

Seletinoid G is a retinoic acid receptor (RAR) agonist. Seletinoid G can repair altered connective tissue in old skin and inhibit UV-induced collagen deficiency in young skin. Seletinoid G can be used for skin aging and photoaging research.

Selenotifen (BN 52256) is an antiallergic agent. Selenotifen is a highly potent antagonist to PAF receptors. Selenotifen exhibits a statistically significant antiarrhythmic effect.

Selenodiglutathione (GSSeSG) is a selenotrisulfide and the major selenium metabolite conjugated with two glutathione moieties. Selenodiglutathione induces DNA damage, base oxidation, strand breaks, apoptosis. Selenodiglutathione exhibits cytotoxicity against breast cancer cells via preferential cellular uptake and elevation of intracellular selenium levels. Selenodiglutathione is applicable to research related to breast cancer.

SDM25N is a Dengue virus (DENV) inhibitor with an EC50 of 1.9 µM. SDM25N inhibits DENV in a cell type-specific manner. SDM25N restricts genomic RNA replication by targeting the viral NS4B protein. SDM25N can be used for DENV infection research.

SDH-IN-45 is a succinate dehydrogenase BcSDH inhibitor and mycelial growth inhibitor targeting Botrytis cinerea, with an IC50 of 5.97 μg/mL against Botrytis cinerea. SDH-IN-45 inhibits succinate dehydrogenase, a component of the mitochondrial electron transport chain, via a unique binding mode, thereby regulating fungal energy metabolism. SDH-IN-45 causes morphological damage to Botrytis cinerea mycelia, leading to collapse and shrinkage of mycelial structures. SDH-IN-45 exhibits in vitro fungicidal activity against Botrytis cinerea. SDH-IN-45 can be used in research related to cucumber gray mold.

SDH-IN-44 is a succinate dehydrogenase (SDH) inhibitor with an IC50 of 12.5 μg/mL against Alternaria solani. SDH-IN-44 exhibits antifungal activity and inhibits fungal mycelial growth. SDH-IN-44 is applicable to research related to fungal infections.

SDH-IN-37 (Compound A37) is a potent SDH inhibitor, with an IC50 value of 0.0263 μM. SDH-IN-37 is also an antifungal agent. SDH-IN-37 demonstrates antifungal activities against Rhizoctonia solani, S. sclerotiorum and F. graminearum, with EC50 values of 0.0144, 0.882 and 1.99 μg/mL, respectively.

SD3A is an antiplatelet agent. SD3A inhibits granule secretion and GP IIb/IIIa activation. SD3A inhibits mitochondrial function. SD3A has an antiaggregant effect on washed platelets stimulated with Collagen. SD3A results in reduced thrombus formation without affecting coagulation.

SCH-720881 is the active metabolite of Rolapitant. Rolapitant (SCH619734) is a potent, selective, long-acting and orally active neurokinin 1 (NK1) receptor antagonist with a Ki of 0.66 nM. Rolapitant does not interact with CYP3A4. Rolapitant shows potent anti-emetic activity in a ferret emesis model.